

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07D 223/22, 401/12, A61K 31/55	A1	(11) International Publication Number: WO 97/02250 (43) International Publication Date: 23 January 1997 (23.01.97)
<p>(21) International Application Number: PCT/GB96/01565</p> <p>(22) International Filing Date: 27 June 1996 (27.06.96)</p> <p>(30) Priority Data: 101732 30 June 1995 (30.06.95) PT</p> <p>(71) Applicant: PORTELA & CA., S.A. [PT/PT]; Rua João Oliveira Ramos, 87, P-4000 Porto (PT).</p> <p>(71) Applicant (for MW only): WAIN, Christopher, Paul [GB/GB]; A.A. Thornton & Co., Northumberland House, 303-306 High Holborn, London WC1V 7LE (GB).</p> <p>(72) Inventors: BENES, Jan; Rua Visconde Seidbal, 16-4º, esq.-E, P-4200 Porto (PT). SOARES DA SILVA, Patrício, Manuel, Vieira, Araújo; Rua S. João Bosco, 221-5º C, P-4100 Porto (PT).</p> <p>(74) Agents: WAIN, Christopher, Paul et al.; A.A. Thornton & Co., Northumberland House, 303-306 High Holborn, London WC1V 7LE (GB).</p>	<p>(81) Designated States: AU, CN, HU, KR, MW, PL, RU, TR.</p> <p>Published With international search report.</p>	
<p>(54) Title: 10-ACYLOXY-10,11-DIHYDRODIBENZ[a,b]AZEPINE-5-CARBOXAMIDES USEFUL FOR TREATING NERVOUS SYSTEM DISORDERS</p> <p>(57) Abstract</p> <p>Compounds of general formula (I), including all possible stereoisomers, wherein: R is hydrogen, alkyl, aminomethyl, halogenalkyl, aralkyl, cycloalkyl, cycloalkylalkyl, alkoxy, phenyl or substituted phenyl or pyridyl group, are useful in pharmaceutical compositions for treating some central nervous system disorders. The compounds are made by reaction of compound (II) with an acylating agent.</p> <div style="display: flex; justify-content: space-around; align-items: center;"> <div data-bbox="598 760 779 954"> <p style="text-align: right;">(I)</p> </div> <div data-bbox="578 980 758 1134"> <p style="text-align: right;">(II)</p> </div> </div>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Ghana	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LJ	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LJ	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

- 1 -

**10-Acyloxy-10, 11-dihydrodibenz/b, f/azepine-5-carboxamides
useful for treating nervous system disorders**


The present invention relates to substituted dihydrodibenz/b, f/azepines, to the method of their preparation and to pharmaceutical compositions containing them. The compounds have valuable pharmaceutical properties in the treatment of some central and peripheral nervous system disorders.

Compounds with the dibenz/b, f/azepine ring system are well known and some of them have been used widely for treatment of some pathological states in humans. For example dibenz/b, f/azepine-5-carboxamide (carbamazepine) has become established as an effective agent in the management of epilepsy, trigeminal neuralgia and affective disorders. However, its administration in humans is complicated by its potent induction of hepatic oxidative enzymes, by adverse central nervous system effects, and frequent and serious idiosyncratic reactions. An analogue of carbamazepine, 10,11-dihydro-10-oxo-5H-dibenz/b, f/azepine-5-carboxamide (oxcarbazepine, see e.g. German Patent 2.011.087) circumvents the problem of induction of hepatic microsomal enzymes by virtue of its differing metabolic profile, while problems remain with others mentioned above. It was proved that oxcarbazepine is metabolised in mammals to 10,11-dihydro-10-hydroxy-5H-dibenz/b, f/azepine-5-carboxamide which exhibits comparable antiepileptic activity to the parent drug. Use of this metabolite as an antiepileptic drug was described (see e.g. Belgian Patent 747.086), but it is not used in practice, because its preferred oral administration

- 2 -

is hampered by its low bioavailability.

The invention aims to achieve an improvement in some of the above mentioned characteristics and relates to new compounds of general formula I, including all possible stereoisomers



wherein:

R is hydrogen, alkyl, aminoalkyl, halogenalkyl, aralkyl, cycloalkyl, cycloalkylalkyl, alkoxy, phenyl or substituted phenyl or pyridyl group; the term alkyl means carbon chain, straight or branched, containing from 1 to 18 carbon atoms; the term halogen represents fluorine, chlorine, bromine or iodine; the term cycloalkyl represents a saturated alicyclic group with 3 to 6 carbon atoms; the term aryl represents unsubstituted phenyl group or phenyl substituted by alkoxy, halogen or nitro group.

Preferred compounds of formula I include:

1. 10-acetoxy-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide
2. 10-benzoyloxy-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide
3. 10-(4-methoxybenzoyloxy)-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide
4. 10-(3-methoxybenzoyloxy)-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide

- 3 -


5. 10-(2-methoxybenzoyloxy)-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
6. 10-(4-nitrobenzoyloxy)-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
7. 10-(3-nitrobenzoyloxy)-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
8. 10-(2-nitrobenzoyloxy)-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
9. 10-(4-chlorobenzoyloxy)-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
10. 10-(3-chlorobenzoyloxy)-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
11. 10-(2-acetoxybenzoyloxy)-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
12. 10-propionyloxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
13. 10-butyryloxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
14. 10-pivaloyloxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
15. 10-[(2-propyl)pentanoyloxy]-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
16. 10-[(2-ethyl)hexanoyloxy]-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
17. 10-stearoyloxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
18. 10-cyclopentanoyloxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
19. 10-cyclohexanoyloxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
20. 10-phenylacetoxo-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
21. 10-(4-methoxyphenyl)acetoxo-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
22. 10-(3-methoxyphenyl)acetoxo-10,11-dihydro-5H-dibenz/b,f/azepine-5-

- 4 -

carboxamide

23. 10-(4-nitrophenyl)acetoxyl-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
24. 10-(3-nitrophenyl)acetoxyl-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
25. 10-nicotinoyloxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
26. 10-isonicotinoyloxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
27. 10-(4-aminobutanoyloxy)-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
28. 10-(2-amino-3-methylbutanoyloxy)-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
29. 10-chloroacetoxyl-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
30. 10-bromoacetoxyl-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
31. 10-formyloxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
32. 10-ethoxycarbonyloxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
33. 10-(2-chloropropionyloxy)-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide

Another aspect of the invention comprises the method of preparation of compounds of formula I where substituent R is defined above, by reacting a compound of formula II



- 5 -

with a compound of the general formula III



III

wherein:

R is the same as defined above for general formula I;

A is hydroxy, halo or -O-CO-R group or -O-CO-OR' group, wherein R' is lower alkyl (C₁-C₄).

Preferably, the process is conducted in the presence of a condensing agent such as dicyclohexylcarbodiimide, carbonyldiimidazole and ethyl- or isobutylchloroformate and/or in the presence of organic or inorganic bases such as pyridine, triethylamine, quinoline, imidazole or alkyl carbonates. Inert solvents may be used, such as hydrocarbons (e.g. hexane, cyclohexane), ethers (e.g. diethylether, tetrahydrofuran), chlorinated alkanes (e.g. dichloromethane, 1,2-dichloroethane) or aprotic dipolar solvents (e.g. acetonitrile, dimethylformamide), or the reaction can be run in a mixture of the above mentioned solvents or in the absence of any solvent.

The acylation reaction described above may be performed at various temperatures and pressures, e.g. between 0°C and the boiling temperature of the reaction mixture, and at atmospheric or elevated pressure.

Compounds of formula II are known (see e.g. German Patent 2.011.045), and compounds of formula III are also well known and can be made by methods known to those skilled in the art, including e.g. methods described in "Comprehensive Organic Transformations" by Richard C. Larock, VCH Publishers, 1989, pp 966 to 972.

In the processes described above, it is sometimes necessary to protect certain functional groups during the reactions. Conventional protecting groups such as benzyloxycarbonyl- or tertbutoxycarbonyl- are operable and can be removed after acylation by standard procedures.

In another aspect, the invention provides a pharmaceutical composition comprising a compound of formula I and a pharmaceutically

- 6 -

acceptable carrier therefor. Such compositions can be made by mixing the compound with the carrier.

Compounds of formula I have valuable pharmaceutical properties in the treatment of some central and peripheral nervous system disorders, namely in treatment of epilepsy, trigeminal neuralgia, affective brain disorders and nervous function changes in degenerative and post-ischemic diseases.

Epilepsy is one of the most common afflictions of man with a prevalence of approximately 1%. Since the time of Hughlings Jackson more than 100 years ago, epileptic seizures have been known to represent "occasional, sudden, excessive, rapid and local discharges of nerve tissue". Epileptic seizures are divided fundamentally into two groups: partial and generalised. Partial seizures are those in which the discharge begins locally, and often remains localised. Generalised seizures involve the whole brain, including the reticular system, thus producing abnormal electrical activity throughout both hemispheres and immediate loss of consciousness. Partial seizures are divided in : (a) *partial simple seizures*, (b) *complex partial seizures* and (c) *partial seizures secondarily generalised*. The generalised seizures include: (1) tonic-clonic seizures (grand mal), (2) absence seizures (petit mal), (3) myoclonic seizures, (4) atonic seizures, (5) clonic seizures and (6) tonic seizures. Epilepsy, in contradistinction to seizures, is a chronic disorder characterised by recurrent seizures (Gastaut, H.: Dictionary of epilepsy. World Health Organization, Geneva, 1973).

There are two ways in which drugs might abolish or attenuate seizures: (a) through effects on altered neurones of seizure foci to prevent or reduce their excessive discharge, and (b) through effects that would reduce the spread of excitation from seizure foci and prevent disruption of function of normal aggregates of neurones. The majority, if not all, of the available antiepileptic drugs work at least by the second mechanism, since all modify the ability of the brain to respond to various seizure-evoking stimuli. Convulsant drugs, such as pentylenetetrazol (metrazol) are often used, particularly in the testing of anticonvulsant agents, and seizures caused by electrical stimulation of the whole

- 7 -

brain are used for the same purpose. It has been found empirically that activity in inhibiting metrazol-induced seizures and in raising the threshold for production of electrically induced seizures is a fairly good index of effectiveness against absence seizures. On the other hand, activity in reducing the duration and spread of electrically induced convulsions correlates with effectiveness in controlling other types of epilepsy, such as tonic-clonic seizures.

The anticonvulsant effect of compounds of formulae I was studied in a model of electrically induced convulsions, the maximal electroshock (MES) test, and in a model of chemical induced convulsions, the metrazol test. The MES test allows the evaluation of the ability of drugs to prevent electrically induced tonic hindlimb extension in rats, the efficacy of which is thought to be predictive of anticonvulsant efficacy against generalised tonic-clonic seizures in man (grand mal). The metrazol test predicts the ability of potential antiepileptic agents to prevent clonic seizures and to be effective against absence seizures (petit mal).

Materials and methods

Male Wistar rats obtained from the animal house of the Instituto Gulbenkian de Ciência (Oeiras, Portugal) and weighing 180 to 280 g were used. Animals were kept two per cage under controlled environmental conditions (12 hr light/dark cycle and room temperature 24°C). Food and tap water were allowed *ad libitum* and the experiments were all carried out during daylight hours.

1 - MES test

MES stimulation was applied for 0.2 s, using a Ugo Basile ECT unit 7801, with a frequency of 100 Hz, pulse width of 0.6 ms and a current of 150 mA through bipolar corneal electrodes. A drop of electrolyte/anaesthetic, oxibuprocaine chloride, was applied in the eyes of all animals immediately before placement of corneal electrodes. Abolition of the hindleg tonic extensor

- 8 -

component, was used as the endpoint. These experimental conditions produced tonic-clonic convulsions in 97% of animals tested and only rats showing typical tonic-clonic convulsions were used. All rats were submitted to a maximum of 3 MES sessions: the first MES session was performed to screen the animals and select those rats presenting a typical convulsive behaviour. The day after, rats were given the compounds to be tested or the vehicle and submitted to a second MES session 2 or 4 hours after the administration of test drugs. The third MES session was performed at 6, 8 or 12 hours after the administration of test drugs. The time interval between each MES session was at least 4 hours (rats tested at 2 hours were retested at 6 hours and rats tested at 4 hours were retested at 8 hours). The evaluation of the anticonvulsive profile of test drugs was based on the duration of the tonic phase (in seconds) being each rat its own control (internal control) as obtained in the first MES session. An external control group was also studied; in this particular case, rats were given the vehicle and submitted to the three MES sessions procedure, as described above. All drugs used were suspended in 0.5% carboxymethylcellulose (4 ml/kg) and given by stomach tube.

2 - Metrazol test

Administration of compounds of formula I was performed 2 hours before the administration of metrazol. Metrazol (75 mg/kg) was given subcutaneously in the back; this dose of metrazol was found to produce convulsions in 95% of the animals. The parameters observed concern the duration of seizures in a 30 minute observation period following the administration of metrazol. ED_{50} (mg/kg) is the dose giving 50% reduction of duration of the seizure.

Results

1 - MES test

At the highest dose tested (35 mg/kg), compounds of formula I

- 9 -

produced a complete protection against MES after 2 hours of administration. At 4 and 8 hours the protection conferred by compounds of formula I was similar to that produced by the reference compound carbamazepine. At the highest dose tested (35 mg/kg), carbamazepine produced a complete protection against MES after 2 hours of administration; at 4 and 8 hours after administration the protection conferred was still above 80%. The ED_{50} values for carbamazepine at 2, 4 and 8 hours after the administration was 7.95, 15.80 and 2.70 mg/kg, respectively. In contrast to oxcarbazepine and similarly to carbamazepine compounds of formula I were found to be more potent after 8 hours with a ED_{50} value substantially lower than that for oxcarbazepine. The ED_{50} values for compounds of formula I at 2, 4 and 8 hours after the administration was 17.97, 13.90 and 3.90 mg/kg, respectively. Oxcarbazepine performed not so potently as did carbamazepine and compounds of formula I. The ED_{50} values for oxcarbazepine at 2, 4 and 8 hours after the administration was 16.18, 16.28 and 13.24 mg/kg, respectively.

2 - Metrazol test

Compounds of formula I were effective in protecting rats against convulsions induced by metrazol. The highest effective dose of compounds of formula I was 30 mg/kg and reduced the total seizure time by 69%. The ED_{50} value for compounds of formula I was 14.7 mg/kg. Carbamazepine at 30 and 60 mg/kg produced a 41% and 44%, respectively, decrease in total seizure time. Oxcarbazepine performed less potently than did carbamazepine. At 30 and 60 mg/kg oxcarbazepine a 3% and 32% decrease in total seizure time was observed, respectively.

Conclusion

Compounds of formula I possess valuable antiepileptic activity as screened in the MES and metrazol tests and are endowed with greater or similar

- 10 -

anticonvulsant potency to that of reference compounds carbamazepine or oxcarbazepine.

The utilisation of compounds of formula I may prove useful in man for the treatment of some other central and peripheric nervous system disorders, e.g. for trigeminal neuralgia and brain affective disorders nervous function alterations in degenerative and post-ischemic diseases.

For the preparation of pharmaceutical compositions from the compounds of formula I, inert pharmaceutically acceptable carriers are admixed with the active compounds. The pharmaceutically acceptable carriers may be either solid or liquid. Solid form preparations include powders, tablets, dispersible granules and capsules. A solid carrier can be one or more substances which may also act as diluents, flavouring agents, solubilizers, lubricants, suspending agents, binders or tablet disintegrating agents; it may also be an encapsulating material.

Preferably, the pharmaceutical preparation is in unit dosage form, e.g. packaged preparation, the package containing discrete quantities of preparation such as packeted tablets, capsules and powders in vials or ampules.

The dosages may be varied depending on the requirement of the patient, the severity of the disease and the particular compound being employed. For convenience, the total daily dosage may be divided and administered in portions throughout the day. Determination of the proper dosage for a particular situation is within the skill of those in the medical art.

The invention disclosed herein is exemplified by the following examples of preparation, which should not be construed to limit the scope of the disclosure. Alternative pathways and analogous structures may be apparent to those skilled in the art.

Example 1: 10-formyloxy-10,11-dihydro-5H-dibenz**b,f**azepine-5-carboxamide

A suspension of 2.54 g (10 mmol) of 10-hydroxy-10,11-dihydro-5H-dibenz**b,f**azepine-5-carboxamide in 50 mL of 1,2-dichloroethane was treated

- 11 -

with 1.23 g (15 mmol) of mixed acetic-formic anhydride and 1.36 g (20 mmol) of imidazole, the mixture was stirred at 25° C for 3 hours and then it was poured into a stirred mixture of 100 mL 0.1 M aqueous HCl and 50 g of ice. The organic layer was separated and extracted with a saturated solution of NaHCO₃, brine, and volatile components were removed by evaporation at reduced pressure. The remaining crude product was purified by chromatography on silica gel eluting first with methylene chloride and then with 1% methanol-methylene chloride mixture to give the desired product as white crystals of m.p. 202 to 203°C.

Example 2-3:

By the application of the above described technique and related procedures known to those skilled in the art, and using appropriate anhydrides, 10-propionyloxy-10,11-dihydro-5H-dibenz**b,f**azepine-5-carboxamide and 10-butyryloxy-10,11-dihydro-5H-dibenz**b,f**azepine-5-carboxamide were prepared.

Example 4: (+)-10-acetoxy-10,11-dihydro-5H-dibenz**b,f**azepine-5-carboxamide

A solution of 9.42 g (0.12 mol) of acetylchloride in 100 mL of dichloromethane was added dropwise to a stirred and cooled (<10°C) suspension of 25.4 g (0.1 mol) of (-)-10-hydroxy-10,11-dihydro-5H-dibenz**b,f**azepine-5-carboxamide in 500 mL of dichloromethane and 11.9 g (0.15 mol) of pyridine. The reaction mixture was then stirred and boiled for two hours, then cooled to 5°C and extracted subsequently with 500 mL of each 0.2 M aqueous sulphuric acid, saturated aqueous sodium bicarbonate and brine. Organic phase was dried by sodium sulphate, filtered through a short pad of silica gel and volatile components of the filtrate were removed by evaporation under reduced pressure. The residue was crystallised from a mixture of dichloromethane and ethyl acetate to give the desired compound as white crystals (m.p. 186 to 187° C), $[\alpha]_D^{20} = +21.5^\circ$ (c=1, pyridine).

Example 5-17:

By the application of the above described technique and related procedures known to those skilled in the art, but using appropriate acid halogenides, following compounds were prepared:

10-benzoyloxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
10-(4-methoxybenzoyloxy)-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
10-(4-nitrobenzoyloxy)-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
10-(4-chlorobenzoyloxy)-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
10-ethoxycarbonyloxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
10-(2-acetoxybenzoyloxy)-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
10-pivaloyloxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
10-stearoyloxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
10-phenylacetoxo-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
10-chloroacetoxo-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
10-bromoacetoxo-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
10-(2-chloropropionyloxy)-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide

Example 18: 10-nicotinoyloxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide

To a stirred suspension of 0.254 g (1 mmol) of 10-hydroxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide and 0.130 g (1 mmol) of nicotinic acid in 5 mL of tetrahydrofuran, 0.230 g (1.1 mmol) of dicyclohexylcarbodiimide and 0.02 g (0.2 mmol) of 4-dimethylaminopyridine was added, and the mixture was stirred at 20°C for six hours. Precipitated urea was removed by filtration, and the filtrate was evaporated under reduced pressure. The residue was chromatographed on silica gel with 0.5% methanol-dichloromethane mixture. Chromatographically homogeneous fractions were pooled, the solvents were distilled off under reduced pressure, and the residue was crystallised from acetonitrile to give the desired compound (m.p. 196 to 198°C).

Example 19-23:

By the application of the above described technique and related procedures known to those skilled in the art, but using appropriate acids, following compounds were prepared:

10-[(2-propyl)pentanoyloxy]-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide
10-[(2-ethyl)hexanoyloxy]-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide
10-cyclohexanoyloxy-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide
10-(4-methoxyphenyl)acetoxy-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide
10-(4-nitrophenyl)acetoxy-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide

Example 24: 10-(4-aminobutanoyloxy)-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide

A solution of isobutyl chloroformate (0.144 g, 1.05 mmol) in 2 mL of tetrahydrofuran was slowly added to a solution of 0.204 g (1 mmol) of N-tert-butoxycarbonyl-gamma-aminobutyric acid and 0.106 g (1.05 mmol) of triethylamine in 3 mL of tetrahydrofuran. The reaction mixture was stirred for 1 hour at -5°C, then filtered and the filtrate was added slowly to a suspension of 0.254 g (1 mmol) of 10-hydroxy-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide in 5 mL of tetrahydrofuran and 0.09 g (1.1 mmol) of pyridine. The reaction mixture was stirred for 4 hours at 25°C, then poured into 50 mL of a cold 5% solution of KHSO₄ and extracted with dichloromethane. The organic layer was extracted with a saturated aqueous solution of NaHCO₃ and brine, dried by sodium sulphate and volatile components were removed by distillation under reduced pressure. The residue was chromatographed on silica gel with 0.5% methanol in dichloromethane. Homogenous fractions were pooled and the solvent was evaporated in vacuo. The remaining protected derivative was dissolved in 10 mL of dichloromethane and 2 mL of trifluoroacetic acid. The reaction mixture was stirred for one hour at room temperature and then extracted with a cold saturated solution of NaHCO₃ and brine. The organic layer was dried by magnesium sulphate, evaporated to a small volume under reduced pressure,

- 14 -


and then diluted with 5 mL of diethyl ether, and 2 mL of a 2% solution of HCl in diethyl ether were added. The precipitated crystals were collected by filtration and dried to give the hydrochloride of the desired compound. The salt was resuspended in 5 mL of aqueous solution of 2% sodium carbonate and extracted with 10 mL of dichloromethane. The organic solvent was dried by sodium sulphate and evaporated under reduced pressure to leave the desired product as an amorphous solid which decomposes without melting at approx. 120°C.

Example 25:

Using similar procedure to that described in the preceeding example but employing the appropriate acid, 10-(2-amino-3-methylbutanoyloxy)-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide was prepared.

Claims:

1. Compounds of general formula I, including all possible stereoisomers



I

wherein:

R is hydrogen, alkyl, aminoalkyl, halogenalkyl, aralkyl, cycloalkyl, cycloalkylalkyl, alkoxy, phenyl or substituted phenyl or pyridyl group; wherein the term alkyl means a straight or branched carbon chain containing from 1 to 18 carbon atoms; the term halogen means fluorine, chlorine, bromine or iodine; the term cycloalkyl means an alicyclic saturated group with 3 to 6 carbon atoms; and the term aryl means an unsubstituted phenyl group or phenyl substituted by an alkoxy, halogen or nitro group.

2. A compound as defined in claim 1 which is:

- (1) 10-acetoxy-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide
- (2) 10-benzoyloxy-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide
- (3) 10-(4-methoxybenzoyloxy)-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide
- (4) 10-(3-methoxybenzoyloxy)-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide
- (5) 10-(2-methoxybenzoyloxy)-10,11-dihydro-5H-dibenz[b,f]azepine-5-

- 16 -


carboxamide

- (6) 10-(4-nitrobenzoyloxy)-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
- (7) 10-(3-nitrobenzoyloxy)-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
- (8) 10-(2-nitrobenzoyloxy)-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
- (9) 10-(4-chlorobenzoyloxy)-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
- (10) 10-(3-chlorobenzoyloxy)-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
- (11) 10-(2-acetoxybenzoyloxy)-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
- (12) 10-propionyloxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
- (13) 10-butyryloxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
- (14) 10-pivaloyloxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
- (15) 10-[(2-propyl)pentanoyloxy]-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
- (16) 10-[(2-ethyl)hexanoyloxy]-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
- (17) 10-stearoyloxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
- (18) 10-cyclopentanoyloxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
- (19) 10-cyclohexanoyloxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
- (20) 10-phenylacetoxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
- (21) 10-(4-methoxyphenyl)acetoxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
- (22) 10-(3-methoxyphenyl)acetoxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide

- 17 -

- (23) 10-(4-nitrophenyl)acetoxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
- (24) 10-(3-nitrophenyl)acetoxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
- (25) 10-nicotinoyloxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
- (26) 10-isonicotinoyloxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
- (27) 10-(4-aminobutanoyloxy)-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
- (28) 10-(2-amino-3-methylbutanoyloxy)-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
- (29) 10-chloroacetoxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
- (30) 10-bromoacetoxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
- (31) 10-formyloxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
- (32) 10-ethoxycarbonyloxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide, or
- (33) 10-(2-chloropropionyloxy)-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide.

3. A process for producing a compound having the general formula I




I

- 18 -

wherein:

R is hydrogen, alkyl, aminoalkyl, halogenalkyl, aralkyl, cycloalkyl, cycloalkylalkyl, alkoxy, phenyl or substituted phenyl or pyridyl group, by reacting a compound of the formula II



II

with a compound of the general formula III



III

wherein:

R is the same as defined above for general formula I;

A is hydrogen, halo or -O-CO-R group or -O-CO-OR' group, wherein R' is lower alkyl.

4. A process according to claim 3, wherein the reaction is conducted in the presence of a condensing agent and/or base.
5. A pharmaceutical composition, which comprises a compound of general formula I as defined in claim 1, and a pharmaceutically acceptable carrier therefor.
6. A composition according to claim 5, wherein the said compound is one claimed in claim 2.
7. The use of a compound as claimed in claim 1 or 2 for the

- 19 -

manufacture of a medicament for the treatment of central and peripheric nervous system disorders.

INTERNATIONAL SEARCH REPORT

Date of International Application No.
PCT/GB 96/01565

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D223/22 C07D401/12 A61K31/55

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base used, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	GB,A,1 310 120 (CIBA-GEIGY A.G.) 14 March 1973 cited in the application see the whole document	1-7
Y	DD,A,218 889 (VEB ARZNEIMITTEL DRESDEN) 20 February 1985 see the whole document	1-7
Y	A. KOROLKOVAS: "Essentials of medicinal chemistry" 1988, JOHN WILEY & SONS, NEW YORK XP002012795 see page 101 - page 106	1-7
P,X	US,A,5 466 683 (J. STERLING ET AL.) 14 November 1995 see the whole document	1-7

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principles or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "Z" document member of the same patent family

Date of the actual completion of the international search

6 September 1996

Date of mailing of the international search report

13.09.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentstraan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax. (+31-70) 340-3016

Authorized officer

Allard, M

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 96/01565

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB-A-1310120	14-03-73	AT-A- 294106	15-10-71
		BE-A- 747086	09-09-70
		BG-A- 17600	10-11-73
		CA-A- 920587	06-02-73
		CH-A- 505101	31-03-71
		DE-A- 2011045	08-10-70
		FR-A- 2035999	24-12-70
		NL-A- 7003026	02-10-70
		SE-B- 354069	26-02-73
DD-A-218889		NONE	
US-A-5466683	14-11-95	NONE	